Advertisement

Topics

Acceleron Pharma & Celgene Corporation Company Profile

13:57 EDT 27th May 2018 | BioPortfolio

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair. The company is a leader in understanding the biology of the TGF-beta protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.


News Articles [1415 Associated News Articles listed on BioPortfolio]

Acceleron Pharma Chief Medical Officer Sherman Plans Retirement

Matthew Sherman, chief medical officer of Acceleron Pharma (NASDAQ: XLRN), plans to retire from the Cambridge, MA-based drug developer. Acceleron says Sherman won’t step away until after the compan...

Acceleron starts PULSAR trial for pulmonary arterial hypertension

Acceleron Pharma has started the PULSAR trial, a Phase ll study designed to evaluate the efficacy and safety of sotatercept...Read More... The post Acceleron starts PULSAR trial for pulmonary arterial...

Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, May 8, 2018 at 5:00 p.m. EDT to discuss its first quarter 2018 operating...

Acceleron to Present at the Leerink Partners 7th Annual Global Healthcare Conference

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today annou...

Acceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27, 2018

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, February 27, 2018 at 5:00 p.m. EST to discuss its fourth quarter and ful...

Acceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare Conference

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announ...

Acceleron Pharma Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 19022018] Prices from USD $350

Acceleron Pharma Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Acceleron Pharma Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment...

Acceleron Snags Fast Track Designation for FSHD Therapy ACE-083

Acceleron Pharma Inc. announced its experimental facioscapulohumeral muscular dystrophy (FSHD) treatment ACE-083 garnered the Fast Track designation from the U.S. Food and Drug Administration.

PubMed Articles [20 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Moving pharma contracting into the era of accountability.

A guide to manufacturing CAR T cell therapies.

In recent years, chimeric antigen receptor (CAR) modified T cells have been used as a treatment for haematological malignancies in several phase I and II trials and with Kymriah of Novartis and Yescar...

Rejuvenating the Face: An Analysis of 100 Absorbable Suture Suspension Patients.

Absorbable suture suspension (Silhouette InstaLift, Sinclair Pharma, Irvine, CA) is a novel, minimally invasive system that utilizes a specially manufactured synthetic suture to help address the issue...

Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder.

Photodynamic diagnosis using the optical imaging agent hexaminolevulinate (HAL, Hexvix®, Ipsen Pharma GmbH, Ettlingen, Germany) as an adjunct to white light cystoscopy (WLC) during the initial transu...

Clinical Trials [85 Associated Clinical Trials listed on BioPortfolio]

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a p...

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Multi-center, survival data collection in subjects previously enrolled in Celgene Protocol CC-5013-MDS-003.

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.

Rollover study supporting solid tumor and hematological disorder indications from Celgene sponsored CC-486 protocols eligible for participation in the study.

Companies [933 Associated Companies listed on BioPortfolio]

Acceleron Pharma, Celgene Corporation

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth a...

Acceleron Pharma & Celgene Corporation

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth a...

Acceleron Pharma and Celgene Corporation

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The...

Acceleron Pharma, Inc.

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of red blood c...

Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. C...

More Information about "Acceleron Pharma & Celgene Corporation" on BioPortfolio

We have published hundreds of Acceleron Pharma & Celgene Corporation news stories on BioPortfolio along with dozens of Acceleron Pharma & Celgene Corporation Clinical Trials and PubMed Articles about Acceleron Pharma & Celgene Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Acceleron Pharma & Celgene Corporation Companies in our database. You can also find out about relevant Acceleron Pharma & Celgene Corporation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record